India High Court Blocks Contentious Zandu Annual Meeting
This article was originally published in PharmAsia News
India's Bombay High Court blocked the annual general meeting of Zandu Pharmaceutical Works, with the assent of two parties fighting over the firm. Chairman Y.P. Trivedi, also an independent director of Zandu, said the cancellation of the meeting would give the opposing parties, Emami and the Parikhs, time to resolve their differences. The agenda of the meeting had included appointment of five nominees by the Parikhs to the company board, a move opposed by Emami. (Click here for more
You may also be interested in...
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.